IDEAYA Biosciences reports Q3 2026 results, files NDA for darovasertib and reaffirms cash runway to 2030
IDEAYA Biosciences announced its third‑quarter 2026 financials, posting a net loss of $125.7 million and GAAP earnings per share of -$1.22. The company completed a new‑drug application for darovasertib plus crizotinib in metastatic uveal melanoma and disclosed a cash balance of $1.15 billion, keeping its cash‑runway guidance into 2030 unchanged. It also said it will close the Phase 3 OptimUM‑010 trial, expecting $100‑125 million in cost savings that will be redirected to other pipeline programs.
Why it matters
The company’s cash runway to 2030 suggests it can fund ongoing development without immediate financing, which is material for investors assessing liquidity risk. The widened loss and trial closure indicate higher near‑term expenses but also potential cost savings that could improve future cash flow.
Key facts
- 1IDEAYA submitted a new‑drug application for darovasertib plus crizotinib in metastatic uveal melanoma in Q3 2026. prnewswire.com
- 2Net loss for Q3 2026 was $125.7 million, up from $112.5 million in Q2. grafa.com
- 3GAAP EPS for Q3 2026 was -$1.22. seekingalpha.com
- 4Revenue for Q3 2026 was $10.24 million. seekingalpha.com
- 5Cash, cash equivalents and marketable securities were $1.15 billion as of September 30 2026. prnewswire.com
- 6The company expects cost savings of $100‑125 million from closing the Phase 3 OptimUM‑010 trial. prnewswire.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.